Gilead Entered into a Clinical Trial Collaboration with Merck for Trodelvy (sacituzumab govitecan-hziy) + Keytruda (pembrolizumab) as 1L Treatment of Metastatic NSCLC
Shots:
- The companies collaborated to evaluate the combination of Gilead’s Trodelvy (Trop-2 targeting ADC) + Merck’s Keytruda (anti-PD-1 therapy) in a P-III trial in patients with metastatic NSCLC
- Merck will sponsor a global P-III clinical trial of Trodelvy + Keytruda as a 1L treatment for patients with metastatic NSCLC. Gilead will sponsor a P-II signal-seeking study to evaluate the combinations including pembrolizumab in 1L NSCLC
- Following the collaboration agreement with Gilead, Everest Medicines will also take part in the P-III study in Asia. Trodelvy is being used in metastatic TNBC & UC and is also being developed for HR+/HER2-metastatic breast cancer and metastatic NSCLC
Ref: Gilead | Image: Gilead
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com